Celgene (NASDAQ:CELG) made major headlines in January after releasing impressive phase 3 data for its cancer drug Abraxane in advanced pancreatic cancer. Today, it looked like Peregrine Pharmaceuticals (NASDAQ:PPHM) had some impressive data of its own. Shares of the stock were surging higher as soon as a press release announcing phase 2 results for bavituximab in late-stage pancreatic cancer hit the wire.
Then investors actually looked at the results, and reality set in. Follow along in the video below as health care bureau chief Brenton Flynn discusses why today's investor optimism was so short-lived.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Drug Stocks That Soared This Week: Are They Buys?
Can Catalyst, Sucampo, and Peregrine keep the momentum going?
It's the Little Things That Matter for Peregrine Pharmaceuticals
Peregrine Pharmaceuticals' shares rose 15% in November, and two subtle press releases provided the spark.
Peregrine Pharmaceuticals' Stock Sank in September: Is It Now a Buy?
Peregrine Pharmaceuticals' stock had a rough September. Should investors take advantage of this pullback to add this speculative biopharma to their portfolios?